
https://www.science.org/content/blog-post/nowhere-go
# Nowhere to Go But Up? (December 2011)

## table of contents
1. [SUMMARY](#1-summary)
2. [HISTORY](#2-history)
3. [PREDICTIONS](#3-predictions)
4. [INTEREST](#4-interest)

## 1. SUMMARY
This blog post by Derek Lowe (December 2011) on the Science Magazine blog "In the Pipeline" announces his Perspective piece "Nowhere to Go But Up?" in ACS Medicinal Chemistry Letters. The piece addresses a significant challenge in drug discovery: while high-throughput screening and rational design methods were producing more initial "hits" than ever, the pharmaceutical industry was struggling to convert those hits into viable drug candidates that could advance through clinical development. Lowe was highlighting what would later be widely recognized as the "failure of drug discovery productivity"—the paradox that despite massive investments in new technologies and expanding compound libraries into the millions, the number of new drugs reaching the market remained disappointing.

## 2. HISTORY
In the years following this article, the issues Lowe highlighted became central to the pharmaceutical industry's ongoing productivity crisis. Between 2011 and 2024, drug discovery methods underwent significant evolution while facing the same fundamental challenges Lowe described. High-throughput screening (HTS) continued to be widely used, but its limitations became increasingly apparent: the industry discovered that simply screening more compounds didn't solve problems of target validation, toxicity, or the molecular complexity required for clinical success.

Concrete developments in the post-2011 period included:
- **Rising R&D costs and declining productivity**: Pharmaceutical R&D spending continued to increase while the number of new molecular entities approved annually remained relatively flat, confirming that technological advances in screening weren't translating into more approved drugs.
- **Shift to targeted therapies**: The industry moved away from pure high-throughput approaches toward more selective, mechanism-based drug discovery, particularly with the rise of targeted cancer therapies and immunotherapies.
- **Clinical failure rates remained high**: Approximately 90% of drugs entering clinical trials continued to fail, with most failures occurring in Phase II due to lack of efficacy—exactly the problem Lowe was highlighting about early-stage hits not translating to clinical success.
- **Adoption of new technologies**: Fragment-based drug design, structure-based design using advanced crystallography and cryo-EM, and later AI/machine learning approaches gained traction as complements or alternatives to traditional HTS.
- **Rise of biologics**: Large-molecule biologics increasingly dominated new drug approvals, representing a different discovery paradigm than the small-molecule focus of traditional HTS.
- **Industry consolidation continued**: Many major pharmaceutical companies restructured their discovery operations, with some closing research sites as productivity challenges persisted.
- **Academic focus on "undruggable" targets**: Research increasingly focused on difficult targets that traditional screening methods couldn't address, leading to new discovery modalities like protein degradation and molecular glues.

Many pharmaceutical companies that heavily invested in high-throughput screening infrastructure in the 2000s had to significantly modify their strategies post-2011, with some restructuring their discovery operations or outsourcing more early-stage discovery work.

## 3. PREDICTIONS
The article itself appears to be more diagnostic than predictive—identifying a persistent problem in drug discovery rather than making specific prognostications. As a blog post announcement referencing a full Perspective piece, the predictions would most likely be found in the ACS Medicinal Chemistry Letters article itself, which I cannot access. 

However, based on Derek Lowe's typical writing style and the known discourse around drug discovery productivity in 2011, predictions that likely appeared in the full article and their outcomes might have included:

- **Increased focus on target validation**: ✓ Realized—the industry did shift toward better understanding disease biology and target validation before committing to large screening campaigns.
- **Need for better chemical starting points**: ✓ Realized—fragment-based approaches and structure-guided design grew in importance.
- **Importance of translational medicine**: ✓ Realized—more emphasis was placed on understanding clinical relevance early in discovery.
- **That technological advances alone wouldn't solve the productivity problem**: ✓ Confirmed—despite continued investment in automation, AI, and screening technologies, drug discovery productivity remained challenging through 2024.

## 4. INTEREST
**Score: 6**

This 2011 article addresses what became one of the most persistent and important challenges in pharmaceutical research—the productivity paradox in drug discovery—which remained highly relevant through 2024. While it identified an ongoing industry problem rather than introducing entirely new science, its timing during a critical period when the industry was grappling with these issues gives it lasting significance for understanding modern drug discovery challenges.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20111228-nowhere-go.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_